[
  {
    "question": "Case of a child came with areas of sun exposed pigmentation, eye problems & Seizures, Dx?",
    "option_a": "Hypomelanosis",
    "option_b": "Neurocutaneous melanosis",
    "option_c": "correctly corresponds to Xeroderma pigmentosum given the combination of sun",
    "option_d": "is not provided.",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Pediatric Neurology",
    "explanation": "Xeroderma pigmentosum (XP) is a rare, autosomal recessive disorder characterized by defective nucleotide excision repair, which normally removes UV-induced DNA lesions. This defect leads to extreme sensitivity to UV light, resulting in pigmentary changes in sun\u2010exposed areas, ocular abnormalities, and sometimes neurological issues including seizures. Mutations in genes responsible for nucleotide excision repair (XP complementation groups A\u2013G) impair the ability of cells to repair DNA damage caused by ultraviolet radiation. The cumulative unrepaired damage leads to premature aging of the skin, pigmentation abnormalities, and an increased risk of malignancies. In some XP subtypes, neurodegeneration occurs due to toxic accumulation of DNA damage within neuronal tissue, which can manifest as seizures. Patients typically develop freckling or abnormal pigmentation in sun-exposed areas, persistent eye irritation or keratitis, and are at very high risk for developing skin cancers. Neurological manifestations, although variable among complementation groups, may include seizures, cognitive impairment, and ataxia. Diagnosis is based on the clinical history of extreme photosensitivity along with characteristic skin and ocular findings. Differential diagnoses include conditions like hypomelanosis of Ito (which shows streaks or whorls of hypopigmentation without marked UV sensitivity) and neurocutaneous melanosis (characterized by melanocytic nevi rather than pigmentary changes from UV damage). Confirmation may involve cellular assays for DNA repair capacity and genetic testing. Management focuses on rigorous UV protection including the use of broad-spectrum sunscreens, protective clothing, and avoidance of sun exposure. Regular dermatologic examinations are necessary for early detection of skin cancers. Ocular protection and supportive care for neurological symptoms (such as antiepileptics for seizures) are important. In pregnancy and lactation, management remains conservative with an emphasis on UV protection and careful choice of medications (selecting antiepileptics with favorable safety profiles) to avoid fetal exposure to potentially teratogenic drugs. Option A (Hypomelanosis) refers to conditions like hypomelanosis of Ito which present with hypopigmented skin streaks not necessarily related to UV exposure and without the pronounced ocular and neurological involvement seen in XP. Option B (Neurocutaneous melanosis) involves the presence of large or multiple melanocytic nevi and neurological symptoms, but lacks the sun-induced pigment changes typical of XP. Option C correctly corresponds to Xeroderma pigmentosum given the combination of sun-exposed pigmentary changes, eye problems, and seizures. Option D is not provided. \u2022 Early and strict UV protection is the keystone in managing XP. \u2022 Neurological involvement in XP can vary; vigilance for early signs of neurodegeneration is essential. \u2022 Regular dermatologic surveillance is critical to prevent and detect skin cancers at an early stage. Recent research has improved our understanding of genotype\u2013phenotype correlations in XP, leading to more tailored surveillance protocols. There is ongoing investigation into gene therapy and novel pharmacologic approaches to boost DNA repair, although current management remains focused on prevention of UV exposure and early intervention for malignancies.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Child with facial port wine rash, has seizure, what else seen? (Sturge Weber disease)",
    "option_a": "Glaucoma",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Pediatric Neurology",
    "explanation": "Sturge-Weber syndrome (SWS) is a neurocutaneous disorder characterized by a facial capillary malformation (port-wine stain), leptomeningeal angiomas, and ocular anomalies, particularly glaucoma. A somatic mosaic mutation in the GNAQ gene leads to abnormal vascular development, resulting in the formation of capillary malformations on the face and leptomeningeal angiomas in the brain. The abnormal vessels can lead to increased intracranial pressure, calcifications, and seizures, while anterior segment involvement predisposes to glaucoma. Children with SWS often present with a port-wine stain along the distribution of the trigeminal nerve (especially in the V1 region), seizures secondary to leptomeningeal angiomas, and ocular issues such as glaucoma which may lead to visual impairment if untreated. The diagnosis is primarily clinical and based on the presence of the characteristic facial port-wine stain in conjunction with neurological (seizures) and ophthalmologic (glaucoma) findings. Neuroimaging (contrast-enhanced MRI or CT scans showing leptomeningeal enhancement or calcifications) and comprehensive ophthalmologic evaluations help secure the diagnosis. Differential diagnoses include other vascular malformations and phakomatoses, but the combination seen in SWS is distinctive. Management involves controlling seizures with appropriate antiepileptic drugs, regular ophthalmologic follow-up for glaucoma management, and sometimes laser therapy for the facial port-wine stain. During pregnancy and lactation, careful selection of antiepileptics (e.g., lamotrigine or levetiracetam, which are relatively safer) and close ophthalmologic monitoring is important to manage potential risks to the fetus and the nursing infant. Option A (Glaucoma) is the correct additional finding in Sturge-Weber syndrome, making it a key component of its clinical triad. Other options (if provided) would not match the signature ocular involvement seen in SWS. \u2022 The port-wine stain in SWS is typically located in the distribution of the ophthalmic branch of the trigeminal nerve. \u2022 Leptomeningeal angiomas are responsible for the seizures and neurological deficits. \u2022 Early ophthalmologic evaluation is crucial to detect and manage glaucoma before significant vision loss occurs. Recent updates stress early intervention and interdisciplinary management, including the use of safer antiepileptic drugs during pregnancy and lactation. Advances in neuroimaging and genetic testing further support early diagnosis and individualized treatment plans.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Child with hypomelanotic macules, forehead plaques and lower trunk lesions (shagreen patches). What else associated? Scenario of TSC.",
    "option_a": "Subependymal nodules",
    "option_b": "Optic glioma",
    "option_c": "Vestibular schwannoma",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Pediatric Neurology",
    "explanation": "Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous disorder that leads to the formation of benign hamartomas in multiple organs, prominently affecting the skin and brain. Skin manifestations include hypomelanotic macules (ash-leaf spots), facial plaques, and shagreen patches. Mutations in either the TSC1 or TSC2 gene result in dysregulation of the mTOR pathway, leading to uncontrolled cell proliferation and the formation of hamartomas. In the brain, this manifests as cortical tubers, subependymal nodules, and occasionally subependymal giant cell astrocytomas (SEGAs), which contribute to seizures and neurocognitive deficits. The presence of hypomelanotic macules, forehead plaques, and shagreen patches is highly suggestive of TSC. The involvement of the central nervous system, as indicated by subependymal nodules, often results in seizures and developmental delays. Recognizing these dermatological signs prompts further neuroimaging to identify brain lesions. Diagnosis is made based on clinical criteria (major and minor features) and can be confirmed with genetic testing. Neuroimaging with MRI can reveal subependymal nodules and cortical tubers. Differential diagnoses include neurofibromatosis type 1 (which presents with caf\u00e9-au-lait spots and neurofibromas) and other phakomatoses, but the unique combination of skin findings in TSC is diagnostic. Management is multidisciplinary and includes seizure control with antiepileptic drugs, mTOR inhibitors (such as everolimus) for managing SEGAs and renal angiomyolipomas, and regular surveillance imaging. In pregnancy and lactation, medication choices for seizure control and mTOR inhibitors should be carefully considered due to teratogenic risks; multidisciplinary consultation and adjustment of doses are recommended to minimize fetal and neonatal exposure. Option A (Subependymal nodules) is correct, as these lesions are a hallmark of TSC and are commonly seen on brain imaging. Option B (Optic glioma) is typically associated with neurofibromatosis type 1, and Option C (Vestibular schwannoma) is most commonly seen in neurofibromatosis type 2. \u2022 Cutaneous signs such as ash-leaf spots and shagreen patches are early clues to the diagnosis of TSC. \u2022 Subependymal nodules should prompt regular neuroimaging surveillance to monitor for potential growth into SEGAs. \u2022 Early multidisciplinary intervention can improve neurological outcomes in TSC patients. Recent guidelines emphasize the role of mTOR inhibitors in reducing the size of SEGAs and other TSC-associated tumors. Advances in genetic testing have further refined diagnostic criteria, and ongoing research is aimed at optimizing long-term management strategies, especially in reproductive-age patients.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Hyperammonemia, low Lcitrulline ?",
    "option_a": "(Urea cycle disorder) is correct because the combination of hyperammonemia with low plasma citrulline is most consistent with a proximal urea cycle enzyme deficiency such as CPS1 or OTC deficiency. Other potential causes of hyperammonemia, like organic acidemias or liver failure, usually present with additional derangements and do not characteristically exhibit low citrulline.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Pediatric Neurology",
    "explanation": "Urea cycle disorders (UCDs) are metabolic conditions caused by enzyme deficiencies in the urea cycle, leading to impaired ammonia detoxification. A common laboratory profile in proximal UCDs is hyperammonemia with low plasma citrulline levels. Defects in early enzymes of the urea cycle, such as carbamoyl phosphate synthetase I (CPS1) or ornithine transcarbamylase (OTC), cause an accumulation of ammonia due to an inability to convert it to urea. Because these enzymes are upstream of citrulline synthesis, their deficiency leads to low citrulline levels. Elevated ammonia is neurotoxic and can lead to encephalopathy and seizures. Patients with UCDs present with signs of hyperammonemic encephalopathy including lethargy, vomiting, irritability, and seizures. The biochemical pattern of high ammonia coupled with low citrulline is key to distinguishing proximal urea cycle defects from other metabolic disorders. The diagnostic workup involves measuring plasma ammonia and amino acid levels. In proximal UCDs, low citrulline is a distinguishing marker, whereas other conditions such as organic acidemias may present with different profiles. Urinary orotic acid can help differentiate OTC deficiency from other proximal disorders. Differential diagnoses include liver failure and organic acidemias, but these typically have additional biochemical derangements. Management involves rapid reduction of ammonia levels using strategies like protein restriction, administration of ammonia scavengers (sodium benzoate, sodium phenylbutyrate), and in severe cases, dialysis. Long-term management may include dietary modifications and, in some instances, liver transplantation. In pregnancy and lactation, management requires careful adjustment of dietary protein and medications to prevent hyperammonemic crises while ensuring maternal and fetal nutritional needs are met; medication regimens should be reviewed for teratogenic risks with a multidisciplinary team approach. Option a (Urea cycle disorder) is correct because the combination of hyperammonemia with low plasma citrulline is most consistent with a proximal urea cycle enzyme deficiency such as CPS1 or OTC deficiency. Other potential causes of hyperammonemia, like organic acidemias or liver failure, usually present with additional derangements and do not characteristically exhibit low citrulline. \u2022 Proximal UCDs are marked by low citrulline levels in the presence of hyperammonemia. \u2022 Early recognition and management of hyperammonemia are critical to prevent irreversible neurological damage. \u2022 Genetic counseling is important for families due to the hereditary nature of UCDs. Recent research has focused on optimizing the dosing and efficacy of ammonia scavengers, as well as investigating novel gene therapies for UCDs. Updated guidelines highlight the importance of early dietary intervention and continual monitoring of biochemical markers, especially in vulnerable periods such as pregnancy and lactation.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "ADHD, hypermelanotic dx",
    "option_a": "(NF1) is correct because it uniquely combines the clinical findings of hypermelanotic caf\u00e9",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Pediatric Neurology",
    "explanation": "Neurofibromatosis type 1 (NF1) is a neurocutaneous disorder characterized by multiple caf\u00e9-au-lait spots, neurofibromas, and often associated neurodevelopmental issues including ADHD. The presence of hypermelanotic skin lesions alongside ADHD symptoms is a classic presentation for NF1. NF1 is caused by an autosomal dominant mutation in the NF1 gene, which encodes neurofibromin\u2014a protein that normally down-regulates the Ras pathway. Loss of function leads to increased cellular proliferation and dysregulated development. The neurodevelopmental abnormalities, including ADHD, are thought to relate to this dysregulation, impacting central nervous system maturation. Patients typically present with multiple caf\u00e9-au-lait macules, freckling in the axillary or inguinal regions, and Lisch nodules (iris hamartomas). In addition, learning disabilities and attention deficit hyperactivity disorder (ADHD) are commonly observed, linking the cutaneous findings with neurodevelopmental issues. The diagnosis is primarily clinical, based on the NIH diagnostic criteria (which include caf\u00e9-au-lait spots, neurofibromas, Lisch nodules, and family history). Differential diagnoses include Legius syndrome (which presents with caf\u00e9-au-lait spots without neurofibromas), NF2 (characterized by bilateral vestibular schwannomas), and tuberous sclerosis (marked by hypomelanotic rather than hypermelanotic lesions). Management is multidisciplinary. First-line management includes regular monitoring for complications (e.g., optic pathway gliomas, learning disabilities) and symptomatic treatment of ADHD. Behavioral interventions and stimulant medications (e.g., methylphenidate) are often used for ADHD, with careful consideration in pregnancy and lactation since some agents are category C. Genetic counseling is also recommended. Second-line therapies may be considered based on evolving symptomatology. Option A (NF1) is correct because it uniquely combines the clinical findings of hypermelanotic caf\u00e9-au-lait spots and ADHD. Legius syndrome (potential alternative) lacks the full neurofibroma picture, NF2 is associated with vestibular schwannomas, and tuberous sclerosis typically presents with hypomelanotic lesions. 1) Caf\u00e9-au-lait spots and Lisch nodules are hallmark features of NF1. 2) ADHD is common in NF1, necessitating early neurodevelopmental evaluation. 3) A family history is often positive due to the autosomal dominant inheritance. Recent studies emphasize the varied neurocognitive impacts of NF1 and highlight the importance of early intervention. Current guidelines advocate for routine surveillance for complications and a tailored approach to managing ADHD symptoms in affected children.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "5 yr old male with developmental delay, showing bilateral symmetrical putamin and GP signal changes",
    "option_a": "(Leigh disease) is correct, corresponding to the MRI findings of symmetrical basal ganglia involvement along with developmental delay. Option B (MELAS) is incorrect because MELAS typically manifests with stroke",
    "option_b": "",
    "option_c": "(MNGIE) does not usually present with the described basal ganglia changes.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Pediatric Neurology",
    "explanation": "Leigh disease is a mitochondrial encephalopathy that typically presents in childhood with developmental delay and a range of neurological deficits. Its hallmark neuroimaging feature is bilateral, symmetrical involvement of the basal ganglia, particularly the putamen and sometimes the globus pallidus. Leigh disease results from defects in mitochondrial energy production, often due to mutations in mitochondrial DNA or nuclear genes affecting oxidative phosphorylation. The energy deficit leads to necrotizing lesions in high-energy demanding regions such as the basal ganglia and brainstem. Children with Leigh disease present with progressive developmental delay, hypotonia, and neurological regression. The symmetric signal changes in the putamen and globus pallidus on MRI are highly suggestive and correlate with the disease\u2019s pathologic necrosis in these metabolically active brain regions. The diagnosis is based on clinical presentation, neuroimaging findings, and laboratory studies that may reveal elevated lactate levels. Differential diagnoses include MELAS (which generally produces stroke-like lesions in the cortex and subcortical regions) and MNGIE (which is associated with gastrointestinal dysmotility and diffuse white matter changes rather than focal basal ganglia involvement). Genetic testing and metabolic studies are important diagnostic tools. Management is primarily supportive. First-line strategies include metabolic support with a 'mitochondrial cocktail' (e.g., thiamine, coenzyme Q10, and other vitamins) and careful management of metabolic crises. There is no definitive cure. In the context of pregnancy and lactation, the use of vitamin supplements is considered safe and is often employed to support mitochondrial function, though genetic counseling is essential when risk assessment is needed. Option A (Leigh disease) is correct, corresponding to the MRI findings of symmetrical basal ganglia involvement along with developmental delay. Option B (MELAS) is incorrect because MELAS typically manifests with stroke-like episodes and cortical lesions, and Option C (MNGIE) does not usually present with the described basal ganglia changes. 1) Bilateral symmetric involvement of the putamen and globus pallidus on MRI is highly suggestive of Leigh disease. 2) Mitochondrial disorders should always be considered in children with unexplained neurodevelopmental regression and lactic acidosis. 3) Early metabolic support may help in managing symptoms, although the overall prognosis remains guarded. Recent guidelines underscore the importance of neuroimaging and genetic confirmation in suspected mitochondrial disorders. Research continues into mitochondrial-targeted therapies, but management remains largely supportive.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Babay boy brought with family he has hx of speech, motor issue, his family are concerned about IQ, primary chromosomes national test (something like this) (2 questions about fragile x, read about it)",
    "option_a": "Inherited anti-psychiatric test",
    "option_b": "metabolic test",
    "option_c": "confirm or r/o fragile x syndrome",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Pediatric Neurology",
    "explanation": "Fragile X syndrome is the most common inherited cause of intellectual disability and autism spectrum disorder. It is caused by an expansion of the CGG trinucleotide repeat in the FMR1 gene, leading to its silencing and subsequent deficiency of the fragile X mental retardation protein (FMRP). The expansion of the CGG repeat (typically over 200 repeats in full mutation) results in hypermethylation of the FMR1 gene and loss of FMRP, a protein necessary for normal neural synaptic development. This deficiency disrupts synaptic connectivity, leading to the developmental, cognitive, and behavioral issues observed. Affected individuals often have speech and motor delays, cognitive impairment, and may display features such as a long face, large ears, and, eventually in post-pubertal males, macroorchidism. The clinical suspicion is typically confirmed by genetic testing, especially when screening tests indicate chromosomal abnormalities related to intellectual disability. Diagnosis is confirmed through molecular genetic tests such as PCR and Southern blot analysis to detect the CGG repeat expansion in the FMR1 gene. Differential diagnoses include other causes of intellectual disability and autism spectrum disorders, but the presence of characteristic physical features and family history typically points to Fragile X syndrome. There is no cure for Fragile X syndrome; management is multidisciplinary and focuses on early intervention with speech, occupational, and behavioral therapies. Pharmacotherapy may be employed to manage ADHD or anxiety symptoms if present. In pregnancy and lactation, it is crucial to provide appropriate genetic counseling for families at risk. Prenatal testing and family planning support are recommended as part of the overall management strategy. Option C is correct as it directly addresses the need for confirmatory genetic testing to rule in or rule out Fragile X syndrome. Option A (an inherited anti-psychiatric test) and Option B (a metabolic test) do not address the underlying genetic etiology of Fragile X syndrome. 1) Fragile X syndrome is the most common inherited cause of intellectual disability. 2) FMR1 gene analysis via PCR and Southern blot is the gold standard in diagnosis. 3) Early intervention can significantly improve functional outcomes in affected children. Current research continues to explore targeted treatments addressing the synaptic dysfunction in Fragile X syndrome. Guidelines recommend routine screening of children with intellectual disability for FMR1 mutations, facilitating early diagnosis and intervention.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "7 yrs boy came myoclonic epilepsy with cognitive decline hypotonia, pathology showed lysosome accumulation.",
    "option_a": "Gaucher",
    "option_b": "Calven",
    "option_c": "Neuronal ceroid lipofuscinosis",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Pediatric Neurology",
    "explanation": "Neuronal ceroid lipofuscinosis (NCL), commonly known as Batten disease, represents a group of lysosomal storage disorders characterized by the accumulation of autofluorescent lipopigments in neurons. It typically presents in childhood with neurodegenerative symptoms. NCL is caused by mutations in different genes that impair lysosomal function, leading to the accumulation of lipofuscin within neurons. This buildup interferes with normal cellular functions, resulting in progressive neurodegeneration. Multiple genetic subtypes exist, each associated with a variable age of onset and clinical course. Clinically, children present with a progressive decline in cognitive function, myoclonic epilepsy, vision loss, and motor disturbances such as hypotonia. The typical age of onset in the juvenile form is around school age, which fits the clinical picture described in the question. Diagnosis is made through a combination of clinical evaluation, neuroimaging, and sometimes enzymatic or genetic testing. The differential diagnosis includes other progressive myoclonic epilepsies like Lafora disease and some metabolic or mitochondrial disorders; however, the lysosomal accumulation of lipopigments is a distinguishing feature of NCL. Management is supportive and symptom-based, focusing on seizure control (using antiepileptic drugs), physical and occupational therapy, and supportive care to improve quality of life. There is no disease-modifying treatment presently available. For families considering future pregnancies, genetic counseling is crucial. In pregnancy and lactation, management remains supportive with interventions tailored to symptom relief rather than curative intent. Option C (Neuronal ceroid lipofuscinosis) is correct because it most accurately fits the combination of myoclonic epilepsy, cognitive decline, hypotonia, and the pathological finding of lysosomal accumulation. Option A (Gaucher) typically presents with hepatosplenomegaly and bone issues, and Option B (Calven) is not a recognized disorder in this context. 1) Juvenile neuronal ceroid lipofuscinosis commonly presents with a combination of myoclonic seizures and progressive cognitive decline. 2) Lysosomal accumulation of lipofuscin is the pathological hallmark. 3) Early genetic counseling is essential for affected families. Ongoing research in NCL is exploring gene therapy and enzyme replacement approaches, though these remain investigational. Current treatment guidelines emphasize multidisciplinary supportive care to manage symptoms and improve patient quality of life.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Calpinopathy scenario. 16 years old presented with calf hypertrophy",
    "option_a": "FSH",
    "option_b": "LGMD2A",
    "option_c": "LGMD1B",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Pediatric Neurology",
    "explanation": "Calpainopathy refers to a subtype of limb\u2010girdle muscular dystrophy (LGMD2A) caused by mutations in the gene encoding calpain\u20103. It is characterized by progressive proximal muscle weakness with characteristic pseudohypertrophy (especially of the calves). Mutations in the CAPN3 gene lead to a deficiency or dysfunction of calpain\u20103, a muscle-specific protease involved in sarcomere remodeling. Its deficiency results in accumulation of damaged proteins and progressive muscle fiber degeneration. The disease is autosomal recessive. Recent molecular studies further detail abnormal protein folding and proteolytic impairment as key factors in muscle fiber loss. Patients, often adolescents, present with proximal muscle weakness, difficulties with activities like climbing stairs, and calf hypertrophy that may mimic other dystrophies. Laboratory evaluation usually reveals elevated creatine kinase levels indicative of muscle damage. The workup includes a detailed clinical evaluation, creatine kinase measurement, electromyography, and muscle imaging (e.g., MRI). Definitive diagnosis is achieved by muscle biopsy and genetic testing for CAPN3 mutations. Differential diagnoses include facioscapulohumeral muscular dystrophy and other forms of LGMD but clinical findings and molecular studies help distinguish them. There is currently no curative treatment. Management is supportive and includes physical therapy to maintain muscle strength and flexibility, orthopedic interventions, and regular cardiopulmonary evaluation. Genetic counseling is essential. In pregnancy and lactation, management remains supportive with multidisciplinary care to ensure optimal maternal and fetal outcomes, and physiotherapy is continued to reduce deconditioning. Option A (FSH) refers to facioscapulohumeral muscular dystrophy, which typically affects the facial and scapular muscles rather than causing prominent calf hypertrophy. Option B (LGMD2A) is the correct answer, and Option C (LGMD1B) denotes a different, mostly autosomal dominant muscular dystrophy that does not match the calpainopathy profile. 1. Calpainopathy (LGMD2A) is one of the most common forms of limb\u2010girdle muscular dystrophy in certain populations. 2. Calf hypertrophy in a young patient with proximal weakness is a key clue. 3. Genetic testing is critical for an accurate diagnosis and counseling. Recent research has focused on gene therapy and exon\u2010skipping strategies, though these remain experimental. Current guidelines emphasize early diagnosis through molecular testing to enable appropriate supportive management and genetic counseling.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "A child who presented with ADHD and multiple light brown macula on skin, what is the diagnosis",
    "option_a": "NF1",
    "option_b": "TS",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Pediatric Neurology",
    "explanation": "Calpainopathy refers to a subtype of limb\u2010girdle muscular dystrophy (LGMD2A) caused by mutations in the gene encoding calpain\u20103. It is characterized by progressive proximal muscle weakness with characteristic pseudohypertrophy (especially of the calves). Mutations in the CAPN3 gene lead to a deficiency or dysfunction of calpain\u20103, a muscle-specific protease involved in sarcomere remodeling. Its deficiency results in accumulation of damaged proteins and progressive muscle fiber degeneration. The disease is autosomal recessive. Recent molecular studies further detail abnormal protein folding and proteolytic impairment as key factors in muscle fiber loss. Patients, often adolescents, present with proximal muscle weakness, difficulties with activities like climbing stairs, and calf hypertrophy that may mimic other dystrophies. Laboratory evaluation usually reveals elevated creatine kinase levels indicative of muscle damage. The workup includes a detailed clinical evaluation, creatine kinase measurement, electromyography, and muscle imaging (e.g., MRI). Definitive diagnosis is achieved by muscle biopsy and genetic testing for CAPN3 mutations. Differential diagnoses include facioscapulohumeral muscular dystrophy and other forms of LGMD but clinical findings and molecular studies help distinguish them. There is currently no curative treatment. Management is supportive and includes physical therapy to maintain muscle strength and flexibility, orthopedic interventions, and regular cardiopulmonary evaluation. Genetic counseling is essential. In pregnancy and lactation, management remains supportive with multidisciplinary care to ensure optimal maternal and fetal outcomes, and physiotherapy is continued to reduce deconditioning. Option A (FSH) refers to facioscapulohumeral muscular dystrophy, which typically affects the facial and scapular muscles rather than causing prominent calf hypertrophy. Option B (LGMD2A) is the correct answer, and Option C (LGMD1B) denotes a different, mostly autosomal dominant muscular dystrophy that does not match the calpainopathy profile. 1. Calpainopathy (LGMD2A) is one of the most common forms of limb\u2010girdle muscular dystrophy in certain populations. 2. Calf hypertrophy in a young patient with proximal weakness is a key clue. 3. Genetic testing is critical for an accurate diagnosis and counseling. Recent research has focused on gene therapy and exon\u2010skipping strategies, though these remain experimental. Current guidelines emphasize early diagnosis through molecular testing to enable appropriate supportive management and genetic counseling.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Child came with encephalopathy and hyperammonemia; what is the Dx?",
    "option_a": "Urea cycle Disorder.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Pediatric Neurology",
    "explanation": "Calpainopathy refers to a subtype of limb\u2010girdle muscular dystrophy (LGMD2A) caused by mutations in the gene encoding calpain\u20103. It is characterized by progressive proximal muscle weakness with characteristic pseudohypertrophy (especially of the calves). Mutations in the CAPN3 gene lead to a deficiency or dysfunction of calpain\u20103, a muscle-specific protease involved in sarcomere remodeling. Its deficiency results in accumulation of damaged proteins and progressive muscle fiber degeneration. The disease is autosomal recessive. Recent molecular studies further detail abnormal protein folding and proteolytic impairment as key factors in muscle fiber loss. Patients, often adolescents, present with proximal muscle weakness, difficulties with activities like climbing stairs, and calf hypertrophy that may mimic other dystrophies. Laboratory evaluation usually reveals elevated creatine kinase levels indicative of muscle damage. The workup includes a detailed clinical evaluation, creatine kinase measurement, electromyography, and muscle imaging (e.g., MRI). Definitive diagnosis is achieved by muscle biopsy and genetic testing for CAPN3 mutations. Differential diagnoses include facioscapulohumeral muscular dystrophy and other forms of LGMD but clinical findings and molecular studies help distinguish them. There is currently no curative treatment. Management is supportive and includes physical therapy to maintain muscle strength and flexibility, orthopedic interventions, and regular cardiopulmonary evaluation. Genetic counseling is essential. In pregnancy and lactation, management remains supportive with multidisciplinary care to ensure optimal maternal and fetal outcomes, and physiotherapy is continued to reduce deconditioning. Option A (FSH) refers to facioscapulohumeral muscular dystrophy, which typically affects the facial and scapular muscles rather than causing prominent calf hypertrophy. Option B (LGMD2A) is the correct answer, and Option C (LGMD1B) denotes a different, mostly autosomal dominant muscular dystrophy that does not match the calpainopathy profile. 1. Calpainopathy (LGMD2A) is one of the most common forms of limb\u2010girdle muscular dystrophy in certain populations. 2. Calf hypertrophy in a young patient with proximal weakness is a key clue. 3. Genetic testing is critical for an accurate diagnosis and counseling. Recent research has focused on gene therapy and exon\u2010skipping strategies, though these remain experimental. Current guidelines emphasize early diagnosis through molecular testing to enable appropriate supportive management and genetic counseling.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Pediatric patient had hepatosplenomegally, hypotonia, flaccid paralysis, MRI showed WM changes, what is the Dx?",
    "option_a": "Hexosaminidase A",
    "option_b": "Glucocerebrosidase",
    "option_c": "Arylsulphatase",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Pediatric Neurology",
    "explanation": "Calpainopathy refers to a subtype of limb\u2010girdle muscular dystrophy (LGMD2A) caused by mutations in the gene encoding calpain\u20103. It is characterized by progressive proximal muscle weakness with characteristic pseudohypertrophy (especially of the calves). Mutations in the CAPN3 gene lead to a deficiency or dysfunction of calpain\u20103, a muscle-specific protease involved in sarcomere remodeling. Its deficiency results in accumulation of damaged proteins and progressive muscle fiber degeneration. The disease is autosomal recessive. Recent molecular studies further detail abnormal protein folding and proteolytic impairment as key factors in muscle fiber loss. Patients, often adolescents, present with proximal muscle weakness, difficulties with activities like climbing stairs, and calf hypertrophy that may mimic other dystrophies. Laboratory evaluation usually reveals elevated creatine kinase levels indicative of muscle damage. The workup includes a detailed clinical evaluation, creatine kinase measurement, electromyography, and muscle imaging (e.g., MRI). Definitive diagnosis is achieved by muscle biopsy and genetic testing for CAPN3 mutations. Differential diagnoses include facioscapulohumeral muscular dystrophy and other forms of LGMD but clinical findings and molecular studies help distinguish them. There is currently no curative treatment. Management is supportive and includes physical therapy to maintain muscle strength and flexibility, orthopedic interventions, and regular cardiopulmonary evaluation. Genetic counseling is essential. In pregnancy and lactation, management remains supportive with multidisciplinary care to ensure optimal maternal and fetal outcomes, and physiotherapy is continued to reduce deconditioning. Option A (FSH) refers to facioscapulohumeral muscular dystrophy, which typically affects the facial and scapular muscles rather than causing prominent calf hypertrophy. Option B (LGMD2A) is the correct answer, and Option C (LGMD1B) denotes a different, mostly autosomal dominant muscular dystrophy that does not match the calpainopathy profile. 1. Calpainopathy (LGMD2A) is one of the most common forms of limb\u2010girdle muscular dystrophy in certain populations. 2. Calf hypertrophy in a young patient with proximal weakness is a key clue. 3. Genetic testing is critical for an accurate diagnosis and counseling. Recent research has focused on gene therapy and exon\u2010skipping strategies, though these remain experimental. Current guidelines emphasize early diagnosis through molecular testing to enable appropriate supportive management and genetic counseling.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Pediatric had bollus which worsen with sun exposure, and he has conjunctivitis; Dx?",
    "option_a": "Xeroderma pegmentosa.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Pediatric Neurology",
    "explanation": "Xeroderma pigmentosum (XP) is a rare autosomal recessive disorder characterized by defective repair of ultraviolet (UV)\u2010induced DNA damage. Patients present early in life with skin lesions that develop or worsen following sun exposure, and they often show ocular involvement such as conjunctivitis or keratitis. XP results from mutations in genes (commonly XPA to XPG) essential for the nucleotide excision repair pathway. This defect prevents the normal repair of UV-induced thymidine dimers, leading to cumulative DNA damage, early skin aging, and a very high risk of developing skin cancers. Ocular tissues, being exposed to sunlight, are also affected by repeated UV injury. In children, the condition manifests as extreme photosensitivity, with the development of pigmented freckle\u2010like lesions and blistering in sun-exposed areas. Conjunctivitis and other ocular manifestations (such as dry eyes and keratitis) are common, paralleling the dermal sensitivity to UV radiation. Diagnosis is based on clinical history (extreme sensitivity to sunlight with early onset skin changes), physical examination, and sometimes laboratory tests including skin biopsy and specialized DNA repair assays. Differential diagnoses include Bloom syndrome, Cockayne syndrome, and porphyrias; however, these have distinguishing clinical features and laboratory markers. Management centers on strict UV protection: avoidance of sunlight, use of high-SPF sunscreens, protective clothing, and UV-blocking eyewear. Regular dermatological and ophthalmological examinations are essential for early detection and treatment of malignancies. Although there is no cure, experimental gene therapy and antioxidant approaches are under investigation. In pediatric patients, early diagnosis also enables genetic counseling. For any affected female during pregnancy or lactation, emphasis remains on rigorous photoprotection and supportive care as there is no contraindication to these measures. Option A (Xeroderma pigmentosum) is correct because the presentation of sun-exacerbated cutaneous lesions and ocular involvement aligns with XP. Other options, though not listed, would not account for the combination of severe photosensitivity and conjunctivitis seen in this disorder. 1. Extreme photosensitivity with early onset of skin lesions and a high predisposition to skin cancers are hallmarks of XP. 2. Ocular complications in XP include conjunctivitis and keratitis, underscoring the need for UV protection of the eyes. Recent research is focused on understanding the molecular defect in XP and exploring gene therapy and antioxidant strategies. Advances in DNA repair enzyme research hold promise for future targeted treatments, although current management remains preventive.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with Developmental delay and bilateral BG high signal intensity. What is the Dx?",
    "option_a": "Leigh Syndrome",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Pediatric Neurology",
    "explanation": "Leigh syndrome is a mitochondrial disorder that typically presents in infancy or early childhood with developmental delay, neurological regression, and characteristic neuroimaging findings. It is an example of a metabolic encephalopathy. The disorder involves defects in mitochondrial energy production, often due to mutations in mitochondrial DNA or nuclear genes encoding components of the respiratory chain. This impairment leads to reduced ATP production and accumulation of lactate, resulting in necrotizing lesions in the central nervous system. Patients often present with developmental delay, hypotonia, and sometimes respiratory abnormalities. Neuroimaging, especially MRI, characteristically demonstrates bilateral, symmetric lesions in the basal ganglia, brainstem, or other deep grey matter structures. Elevated lactate in serum or CSF further supports mitochondrial dysfunction. Diagnosis is based on a combination of clinical history, neuroimaging findings (symmetric high signal intensity in basal ganglia on T2-weighted MRI), biochemical markers (elevated lactate), and ultimately genetic testing or muscle biopsy. Differential diagnoses include other mitochondrial disorders (e.g., MELAS), metabolic disorders (e.g., pyruvate dehydrogenase deficiency), or Wilson disease, though the age of presentation and imaging patterns help differentiate them. Management is primarily supportive. First-line interventions include nutritional support, physical and occupational therapy, and specific mitochondrial cocktail therapies such as coenzyme Q10 and thiamine supplementation. Second-line approaches focus on symptom management and prevention of metabolic decompensation. In the context of pregnancy and lactation, careful metabolic monitoring is advised, and genetic counseling is essential given the hereditary nature of the disorder. Option A (Leigh syndrome) is correct based on the combination of developmental delay and bilateral basal ganglia lesions seen on imaging. Other differential diagnoses such as MELAS or pyruvate dehydrogenase deficiency might present with similar metabolic disturbances but have differing clinical and radiological profiles. 1. Symmetric basal ganglia involvement on MRI in a child with developmental delay strongly suggests a mitochondrial disorder such as Leigh syndrome. 2. Elevated lactate and metabolic acidosis are key laboratory findings that support the diagnosis. Current studies are exploring targeted therapies to improve mitochondrial function, including the use of antioxidants and redox modulators. Genetic sequencing has improved diagnostic accuracy, although treatment remains largely supportive.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Pediatric had bollus which worsen with sun exposure, and he has conjuctivitis; Dx?",
    "option_a": "Xeroderma pegmentosa.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Pediatric Neurology",
    "explanation": "This pediatric case, featuring lesions that worsen with sun exposure along with conjunctivitis, is characteristic of Xeroderma pigmentosum (XP), a disorder of defective DNA repair. Early presentation in children with significant photosensitivity is the hallmark of this condition. XP is caused by mutations in genes responsible for nucleotide excision repair. The inability to repair UV-induced DNA damage (specifically thymidine dimers) leads to increased mutagenesis, streaked with early onset skin lesions and a predisposition to malignancies. Ocular tissues similarly exposed to UV light develop chronic inflammation, manifesting as conjunctivitis and keratitis. Children with XP present with severe skin sensitivity marked by blistering, freckling, and pigmentary changes predominantly after sun exposure. Ocular findings such as conjunctivitis further corroborate the diagnosis. This clinical picture differentiates XP from other photosensitivity disorders. Diagnosis is largely clinical, supported by a detailed history of extreme photosensitivity and characteristic skin findings. Laboratory tests, such as cellular assays for DNA repair, and genetic testing can confirm the diagnosis. Differential diagnoses include conditions like Bloom syndrome, Cockayne syndrome, and porphyrias, each having distinctive features. The cornerstone of management is rigorous photoprotection including the use of high-SPF sunscreens, protective clothing, and UV-blocking eyewear. Regular dermatologic and ophthalmologic evaluations are essential to detect premalignant and malignant changes early. For pediatric patients and their families, genetic counseling is invaluable. During pregnancy and lactation, management remains similar with an emphasis on strict photoprotection and vigilant skin monitoring. Option A (Xeroderma pigmentosum) is correct as it best explains the combination of sun-sensitive skin lesions and ocular involvement. Alternatives would not adequately account for both aspects of the presentation. 1. Early onset of severe photosensitivity with conjunctival involvement is a red flag for XP. 2. Lifelong strict UV protection is the mainstay of therapy in XP to prevent early malignancies. New research is evaluating gene-based therapies and novel antioxidants to enhance DNA repair, though current management is predicated on preventive measures and early detection of malignancies.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with ADHD light brown lesions",
    "option_a": "is deemed correct if it represents Neurofibromatosis type 1. Caf\u00e9",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Pediatric Neurology",
    "explanation": "This question examines the association between neurocutaneous syndromes and neurodevelopmental disorders. ADHD in the context of light brown skin lesions (caf\u00e9-au-lait macules) is most classically associated with Neurofibromatosis type 1 (NF1). NF1 is caused by mutations in the NF1 gene, which encodes neurofibromin, a protein that helps regulate cell growth and differentiation. The loss of neurofibromin leads to the formation of benign tumors (neurofibromas) and characteristic pigmentary skin changes (caf\u00e9-au-lait spots). Additionally, the involvement of neural pathways can predispose affected individuals to attention deficits and learning disabilities. In clinical practice, patients with NF1 present with caf\u00e9-au-lait macules that are typically light brown and are one of the diagnostic criteria. The prevalence of ADHD in NF1 is significantly higher than in the general pediatric population. This combination of cutaneous findings and neurodevelopmental issues is central to the diagnosis. The diagnosis of NF1 is based on established criteria (e.g., the NIH criteria), which include the presence of two or more caf\u00e9-au-lait macules (of defined size based on age), neurofibromas, freckling in the axillary or inguinal regions, or Lisch nodules on eye examination. Differential diagnoses include Tuberous Sclerosis Complex (which features hypomelanotic \u2018ash leaf\u2019 macules rather than light brown caf\u00e9-au-lait spots) and other neurocutaneous disorders. Genetic testing can support the diagnosis. Management of NF1 is multidisciplinary. First-line management involves routine surveillance for complications including periodic dermatologic, neurologic, and ophthalmologic evaluations. Behavioral therapy and stimulant medications (e.g., methylphenidate) are options for managing ADHD symptoms. Genetic counseling is recommended for affected families. In pregnancy and lactation, treatment of ADHD should follow established guidelines (considering non-pharmacologic interventions first and weighing the risks and benefits of medication), and regular monitoring for NF1-related complications should continue. Option A is deemed correct if it represents Neurofibromatosis type 1. Caf\u00e9-au-lait macules are the hallmark of NF1, and its strong association with ADHD makes it the most appropriate diagnosis. In contrast, Tuberous Sclerosis Complex is characterized by hypomelanotic (ash leaf) macules and a different neuropsychiatric profile, making it less consistent with the described presentation. 1. Caf\u00e9-au-lait spots (light brown macules) in a pediatric patient with ADHD should raise suspicion for NF1. 2. NF1 is one of the most common neurocutaneous disorders, and careful longitudinal follow-up is important due to the risk of complications such as learning disabilities and tumor development. Current research in NF1 focuses on understanding genotype-phenotype correlations and on novel targeted therapies that might modify disease progression. Updated clinical guidelines emphasize the importance of early neurodevelopmental intervention and regular monitoring for associated malignancies and complications.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with Developmental delay and bilateral BG high signal intensity. What is the Dx?",
    "option_a": "leigh Syndrome",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Pediatric Neurology",
    "explanation": "Leigh syndrome, also known as subacute necrotizing encephalomyelopathy, is a mitochondrial disorder that typically presents in infancy or early childhood. It is characterized by developmental delay, hypotonia, and a regression of motor skills. Neuroimaging often reveals bilateral symmetric lesions, particularly in the basal ganglia and brainstem. Leigh syndrome results from defects in mitochondrial energy metabolism due to mutations in mitochondrial DNA or nuclear genes responsible for oxidative phosphorylation. This defect leads to energy depletion in tissues with high metabolic demands like the basal ganglia, causing neuronal injury and necrosis. Recent studies continue to explore the genetic heterogeneity and variable penetrance associated with this disease. Clinically, patients present with developmental delay, progressive neurologic decline, hypotonia, and other brainstem signs. The bilateral high signal intensity on MRI in the basal ganglia correlates with the areas of metabolic stress and necrosis seen in Leigh syndrome. The diagnosis is made based on clinical presentation combined with neuroimaging findings (symmetric lesions in the basal ganglia and brainstem), elevated lactate levels in blood/CSF, and confirmatory genetic testing. Differential diagnoses include other mitochondrial cytopathies, metabolic disorders, or leukodystrophies. Differentiation is achieved via biochemical assays (lactate, pyruvate levels), MRI pattern recognition, and genetic panels. Management is mainly supportive. First-line management involves nutritional support, physical therapy, and the use of mitochondrial cofactors such as thiamine, biotin, coenzyme Q10, and sometimes antioxidants. There is no definitive cure. In pregnancy and lactation, while direct therapy for the neonate does not apply, genetic counseling and prenatal diagnosis for at-risk pregnancies are recommended. Supportive management remains the cornerstone in symptomatic treatment. Option A (Leigh syndrome) is correct because the clinical picture of developmental delay along with bilateral basal ganglia (BG) high signal intensity on MRI is the hallmark of this condition. Other options were not provided, but common differentials such as Wilson\u2019s disease, glutaric aciduria, or other mitochondrial disorders do not fit this classic imaging pattern and developmental presentation as precisely. 1. Symmetrical basal ganglia lesions in a child with developmental delay should always raise suspicion for a mitochondrial disorder like Leigh syndrome. 2. Elevated lactate in blood or CSF often accompanies the imaging findings. 3. Genetic testing plays an important role in confirming the diagnosis. Recent research emphasizes the genetic heterogeneity of Leigh syndrome and encourages early metabolic assessments and genetic counseling. Therapeutic trials for mitochondrial disorders are ongoing, but current guidelines still stress supportive care and symptomatic management.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "What is colpocephaly?",
    "option_a": "Enlarged lateral ventricle",
    "option_b": "Enlarged occipital ventricle",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Pediatric Neurology",
    "explanation": "Colpocephaly is a neurodevelopmental condition where there is a disproportionate enlargement of the occipital horns of the lateral ventricles. The term itself originates from Greek, meaning swelling of the occipital portions of the ventricles. The condition is believed to result from abnormal cerebral development, particularly in disorders that affect the growth of the cerebral hemispheres or the corpus callosum. This leads to a relative reduction in the volume of the adjacent white matter, making the occipital horns appear enlarged on imaging. Patients with colpocephaly may present with developmental delays, intellectual disabilities, and sometimes seizures. The characteristic radiologic finding is the enlargement of the occipital horns while the frontal horns remain less affected. Diagnosis is primarily radiologic. MRI or CT scans reveal disproportionate enlargement of the occipital horns of the lateral ventricles. Differential diagnoses include generalized hydrocephalus (which involves uniform ventricular enlargement) and other structural brain malformations such as agenesis of the corpus callosum. The specific pattern of occipital horn enlargement helps differentiate colpocephaly. Management is generally supportive and symptom-based. Early intervention programs, physical and occupational therapy are used for developmental delays. If seizures are present, antiepileptic drugs may be considered. In the context of pregnancy and lactation, prenatal ultrasound and fetal MRI can help in early detection, and genetic counseling might be offered if associated anomalies are suspected. Option B, stating 'Enlarged occipital ventricle', is correct because colpocephaly specifically refers to the enlargement of the occipital horns of the lateral ventricles, rather than a generalized enlargement of the entire lateral ventricle as might be suggested in option A. 1. Colpocephaly is characterized by a selective enlargement of the occipital horns of the lateral ventricles. 2. It is frequently associated with corpus callosum abnormalities. 3. Neuroimaging is key to its diagnosis. Current literature emphasizes detailed neuroimaging for accurate diagnosis and early developmental interventions. Recent research continues to explore the associations with various midline brain malformations and their prognostic implications.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Infant presented with choreoathetosis, and hearing loss. Brain MRI reported globus pallidus hyperintensity, what is the most likely diagnosis?",
    "option_a": "Kernicterus",
    "option_b": "?",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Pediatric Neurology",
    "explanation": "Kernicterus is a form of bilirubin-induced neurological dysfunction that results from the deposition of unconjugated bilirubin in the brain, particularly in the basal ganglia. Excess unconjugated bilirubin, often secondary to severe neonatal jaundice, crosses the immature blood-brain barrier and accumulates in brain tissue, especially in the globus pallidus. This leads to neuronal injury, apoptosis, and subsequent permanent neurological deficits. Clinically, infants with kernicterus present with movement disorders such as choreoathetosis, rigidity, or hypotonia, in addition to sensorineural hearing loss. The MRI finding of hyperintensity in the globus pallidus is a radiologic hallmark of bilirubin toxicity. Diagnosis is made based on a combination of a history of significant neonatal hyperbilirubinemia, clinical signs of neurological impairment (such as abnormal movements and hearing loss), and neuroimaging findings of basal ganglia involvement. Differential diagnoses might include other metabolic disorders that affect the basal ganglia, but the history of severe jaundice directs the diagnosis toward kernicterus. The primary management strategy for kernicterus is prevention. This includes early detection and treatment of neonatal hyperbilirubinemia with phototherapy and, if necessary, exchange transfusion. Once kernicterus has developed, management is supportive, focusing on rehabilitation and therapies aimed at managing movement disorders. In pregnancy and lactation, emphasis is on ensuring that neonates are monitored carefully for jaundice and that breastfeeding practices support adequate hydration and bilirubin clearance. Option A (Kernicterus) is correct because the combination of choreoathetosis, hearing loss, and the characteristic MRI finding (globus pallidus hyperintensity) are classic for kernicterus, which occurs due to bilirubin toxicity. Other potential conditions do not align as well with this unique presentation. 1. Kernicterus is preventable with early and adequate treatment of neonatal hyperbilirubinemia. 2. The globus pallidus is particularly vulnerable to bilirubin toxicity. 3. Sensorineural hearing loss is a key clinical clue indicating kernicterus. Recent guidelines stress aggressive treatment of neonatal jaundice, with well-defined thresholds for phototherapy and exchange transfusion to prevent kernicterus. Research continues into better understanding the risk factors that predispose infants to bilirubin neurotoxicity.",
    "exam_year": "2024",
    "exam_type": "Part II",
    "image_url": "page_33.png"
  },
  {
    "question": "A 2-week-old infant developed progressive hypotonia and feeding difficulties, has was found to have increased branched amino acid and urine, what is the diagnosis?",
    "option_a": "Urea cycle defect",
    "option_b": "Maple syrup urine disease",
    "option_c": "Methylmalonic acidemias",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Pediatric Neurology",
    "explanation": "Maple syrup urine disease (MSUD) is an inherited metabolic disorder characterized by the inability to break down branched-chain amino acids (leucine, isoleucine, and valine) due to a deficiency in the branched-chain \u03b1-ketoacid dehydrogenase complex. The enzyme deficiency leads to the accumulation of branched-chain amino acids and their corresponding ketoacids in the blood and urine. These toxic metabolites interfere with normal brain development and function, leading to neurological deterioration if left untreated. Infants with MSUD typically present within the first two weeks of life with symptoms such as poor feeding, progressive hypotonia, lethargy, and characteristic movement disorders. The presence of an unusual odor in the urine (often described as resembling maple syrup) is a clinical hallmark. Neurological involvement is reflected in the progressive decline seen in affected newborns. The diagnosis is confirmed by plasma amino acid analysis showing elevated levels of leucine, isoleucine, and valine, along with corresponding ketoacid levels in the urine. Newborn screening programs are designed to detect this condition early. Differential diagnoses include urea cycle defects and other organic acidemias, but these conditions do not typically cause the specific accumulation of branched-chain amino acids. First-line management involves strict dietary restriction of branched-chain amino acids to prevent accumulation of toxic metabolites. Acute management during metabolic crises may require supportive measures such as intravenous fluids, correction of metabolic acidosis, and sometimes dialysis in severe cases. Long-term management includes careful nutritional planning and regular monitoring of amino acid levels. In pregnancy and lactation, affected mothers require specialized dietary counseling to maintain metabolic stability, and neonates should be screened early to initiate prompt treatment. Option B (Maple syrup urine disease) is correct. The description of increased branched-chain amino acids in the urine and the clinical presentation of a 2\u2010week\u2010old infant with progressive hypotonia and feeding difficulties is pathognomonic for MSUD. Other options such as urea cycle defects or methylmalonic acidemias have different metabolic derangements and clinical presentations. 1. MSUD typically presents in the neonatal period with feeding difficulties and hypotonia. 2. The characteristic maple syrup odor in the urine can provide a clinical clue to the diagnosis. 3. Early detection through newborn screening is critical for successful management. Recent advances in newborn screening and metabolic management have improved outcomes in MSUD patients. Research focuses on refining dietary management, potential enzyme replacement, and the role of liver transplantation in severe cases. Current guidelines emphasize rapid intervention to prevent irreversible neurological damage.",
    "exam_year": "2024",
    "exam_type": "Part II"
  }
]